# A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

> **NCT04799054** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ascendis Pharma Oncology Division A/S** · enrollment: 188 (actual)

## Conditions studied

- Advanced Solid Tumor
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
- Head and Neck Squamous Cell Carcinoma HNSCC
- HPV-associated Cancers
- Neoadjuvant Melanoma
- Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)

## Interventions

- **DRUG:** TransCon TLR7/8 Agonist
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04799054
- **Lead sponsor:** Ascendis Pharma Oncology Division A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-18
- **Primary completion:** 2025-12-02
- **Final completion:** 2025-12-02
- **Target enrollment:** 188 (ACTUAL)
- **Why stopped:** The Sponsor made the decision to close enrollment to prioritize our efforts on TransCon IL-2 ß/g.
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04799054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04799054, "A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04799054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*